STAAR lenses granted NTIOL status

Article

The Afinity Collamer aspheric single piece Intraocular Lens (IOL) Model CC4204A and the Elastimide Silicone aspheric IOL Model AQ2015A, both manufactured and marketed by STAAR Surgical, have been designated New Technology IOLs (NTIOLs) by the US Centers for Medicare and Medicaid.

The Afinity Collamer aspheric single piece Intraocular Lens (IOL) Model CC4204A and the Elastimide Silicone aspheric IOL Model AQ2015A, both manufactured and marketed by STAAR Surgical, have been designated New Technology IOLs (NTIOLs) by the US Centers for Medicare and Medicaid. STAAR also already has NTIOL status for the Collamer aspheric three-piece IOL.

NTIOL status, granted if an IOL is able to demonstrate that it provides new clinical benefits, enhances access to the latest IOL technologies to beneficiaries of the Medicare/Medicaid programmes in the US by conferring an additional reimbursement of $50 for each NTIOL provided to these beneficiaries in an Ambulatory Surgical Center (ASC).

The Afinity Collamer single piece lens, which can be implanted through a 2.2 mm incision with the nanoPOINT Injector System (STAAR Surgical), and the Elastimide Silicone lens belong to the Reduced Spherical Aberrations subset of NTIOLs. The additional reimbursement for which these lenses are now eligible will run until 26 February 2011.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.